Agile Therapeutics Balance Sheet - Annual (NASDAQ:AGRX)

Add to My Stocks
$0.34 $0.03 (8.11%) AGRX stock closing price Sep 19, 2018 (Closing)

The fundamental analysis of this company requires a thorough look at Agile Therapeutics balance sheet. As in our Agile Therapeutics stock analysis, analyzing a company also involves looking at the company's assets and liabilities as given in its balance sheet, which can be used to measure financial performance. A company releases its balance sheet every year along with its annual results. Agile Therapeutics had a long term debt of $- at the end of 2017. To understand the debt servicing capacity of the company, one needs to look at Agile Therapeutics operating cash flow and Agile Therapeutics revenue also. Agile Therapeutics debt to equity ratio is .

View latest 10 year balance sheet data to check Agile Therapeutics financial performance.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012
Cash35.95M48.75M34.39M40.18M2.11M20.01M
Marketable Securities------
Receivables------
Inventory------
Raw Materials------
Work In Progress------
Finished Goods------
Notes Receivable------
Other Current Assets-2.76M3.69M---
Total Current Assets
36.71M51.51M38.08M40.98M2.26M20.26M
Property Plant & Equipment14.2M12.65M12.62M12.33M12.23M7.29M
Accumulated Depreciation------
Net Property Plant & Equipment
13.86M12.33M12.31M12.04M11.96M7.02M
Investment & Advances------
Other Non-Current Assets------
Deferred Charges------
Intangibles------
Deposits & Other Assets---1.69M--
Total Assets
50.59M63.86M50.71M54.82M14.4M27.51M
Notes Payable------
Accounts Payable2.78M2.05M2.38M2.63M-1.12M
Current Portion Long-Term Debt------
Current Portion Capital Leases------
Accrued Expenses-3.35M2.65M1.06M--
Income Taxes Payable------
Other Current Liabilities10.63M5.27M2.89M5.29M5.74M-
Total Current Liabilities
14.27M10.67M7.93M8.99M6.84M2.1M
Mortgages------
Deferred Taxes/Income------
Convertible Debt------
Long-Term Debt-10.89M13.03M9.82M9.76M14.78M
Non-Current Capital Leases------
Other Long-Term Liabilities------
Total Liabilities
14.27M21.57M20.96M18.82M85.84M86.12M
Minority Interest----69.23M69.23M
Preferred Stock------
Common Stock Net------
Capital Surplus258.09M235.75M194.46M170.39M46.87M45.38M
Retained Earnings-221.77M-193.46M-164.72M-134.39M-118.31M-103.99M
Treasury Stock------
Other Liabilities------
Shareholders Equity36.32M42.28M29.74M36M-71.44M-58.6M
Total Liabilities & Shareholders Equity50.59M63.86M50.71M54.82M14.4M27.51M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Most investors just check the Agile Therapeutics stock price, and Agile Therapeutics historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Agile Therapeutics PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: AGRX total assets, which was at $50.59M for 2017 is a balance sheet item representing value of what Agile Therapeutics owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. AGRX stock had total liabilities of $14.27M for the year 2017.

Agile Therapeutics Balance Sheet - Key Ratios